Rate My Professor Kathryn Skelding

Skelding's research expertise spans from fundamental biochemistry to the clinical evaluation of new anti-cancer therapeutics. As a molecular biologist with expertise in cell biology, her work investigates the mechanisms underlying cancer cell proliferation, survival, invasion, metastasis, and the development of resistance to chemotherapeutics. Particular emphases include brain cancer, leukaemia—with a strong focus on acute myeloid leukaemia and childhood acute lymphoblastic leukaemia—breast cancer, and prostate cancer. She explores critical signal transduction pathways, such as those involving calcium/calmodulin-stimulated protein kinase II (CaMKII) and brain and acute leukemia cytoplasmic (BAALC) protein, to identify novel inhibitors and targeted therapies that can improve patient outcomes and quality of life. Key publications include "Modeling the Bone Marrow Microenvironment to Better Understand the Pathogenesis, Progression, and Treatment of Hematological Cancers" (2025), "Bone Marrow Microenvironment as a Source of New Drug Targets for the Treatment of Acute Myeloid Leukaemia" (2023), "Calcium/Calmodulin-Stimulated Protein Kinase II (CaMKII): Different Functional Outcomes from Activation, Depending on the Cellular Microenvironment" (2023), "A Novel Role for Brain and Acute Leukemia Cytoplasmic (BAALC) in Human Breast Cancer Metastasis" (2021), and "High Expression of ENO1 and Low Levels of Circulating Anti-ENO1 Autoantibodies in Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukaemia" (2024). Her contributions advance the understanding of cancer biology and therapeutic strategies.